(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 14 October 2004 (14.10.2004)

PCT

(10) International Publication Number WO 2004/087186 A1

(51) International Patent Classification⁷: A61K 35/78, A61P 35/00

(21) International Application Number:

PCT/SG2003/000071

(22) International Filing Date:

3 April 2003 (03.04.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicants (for all designated States except US): MEDI-GEN BIOTECHNOLOGY SINGAPORE PTE. LTD. [SG/SG]; 10 Anson Road, #13-12, International Plaza, Singapore 079903 (SG). MEDIGREEN BIOTECH-NOLOGY CORPORATION [—/—]; 5 FL., N°.611, Sec. 1, Wanshou Rd., Gueishan, Shiang, Taoyuan 333 (TW).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHANG, Hsun-Lang [—/—]; Suite 3, 4 FL., N°72, Jungmei 3rd. St., Hualien City, Hualien 970 (TW). WU-CHANG,

Chuang [—/—]; 3 FL., N°.9, Lane 55, Shinyi Rd., Yunghe City, Taipei 234 (TW). KUO, Wei-Ying [—/—]; 5 FL., N°.27, Lane 384, Jiashing Road, Jubei City, Hsinchu 302 (TW). SHANE, Guang-Tzuu [—/—]; 4 FL., N°.14, Lane 172, Sec. 2, Tun-Hwa S. Road, Taipei (TW). CHANG, Hung-Sheng [—/—]; 2 FL., N°.32-1, Guoguang Rd., Banchiau City, Taipei 220 (TW).

(74) Agent: LORRAINE, Anne Tay; Wong & Leow LLC, 1 Temasek Avenue, #27-01, Millenia Tower, Singapore 039192 (SG).


(81) Designated States (national): AU, CA, CN, DE, GB, JP, US.

(84) Designated States (regional): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(57) Abstract: The present invention relates to a novel composition comprising geranium oil and extracts from the roots of the plants of the genus Sophora, preferably Sophora tonkinesis. Said composition can be administered to mammalian animals undergoing cancer treatments, such as chemotherapy and radiation therapy, that would induce the side effect of bone marrow suppression. The administration can be made before, during and or after the cancer treatment.